On July 1, 2023, Sunovion Pharmaceuticals Inc. became part of Sumitomo Pharma America, Inc.,[1] a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need spanning psychiatry and neurology, oncology, urology, women's health, rare disease, and cell and gene therapies.
Sunovion was founded as Sepracor, Inc. in 1984 by Timothy J. Barberich, Steve Matson, and Bob Bratzler. Sepracor completed its initial public offering in 1991, trading on NASDAQ under the ticker SEPR. On October 12, 2010, Sepracor, Inc. was acquired by and became a standalone subsidiary of Sumitomo Pharma of Japan (then known as Sumitomo Dainippon Pharma). In April 2023, Sumitomo Pharma announced the combination of its U.S. subsidiaries, including Sunovion, to form Sumitomo Pharma America (SMPA).[2]
^"Sumitomo Pharma America Launches as New Combined Organization with Expanded Scale, Resources & Capabilities". Yahoo Finance. 2023-07-10. Retrieved 2023-07-13.
^Armstrong, Annalee (Apr 3, 2023). "Sumitomo Pharma tidies up 7 units into one combined US entity in spring cleaning". Fierce Biotech. Retrieved July 13, 2023.
On July 1, 2023, Sunovion Pharmaceuticals Inc. became part of Sumitomo Pharma America, Inc., a science-based, technology-driven biopharmaceutical company...
Sepracor for $2.6B in 2010, renaming its new stand-alone subsidiary Sunovion. Under Sunovion management, Sumitomo Dainippon Pharma was able to successfully...
medication was discovered in collaboration between PsychoGenics Inc. and Sunovion Pharmaceuticals (which was subsequently merged into Sumitomo Pharma) using...
Novartis licensed its U.S. commercial rights for Arcapta Neohaler to Sunovion Pharmaceuticals. "Arcapta Neohaler (indacaterol) inhalation powder Initial...
ajp.161.6.1113. PMID 15169702. "Latuda Prescribing Information" (PDF). Sunovion Pharmaceuticals. Archived (PDF) from the original on 12 July 2018. Retrieved...
Lundbeck Myriad Genetics Neurocrine Biosciences Otsuka Pharmaceutical Pfizer Sunovion Takeda Pharmaceutical Company Donors to the foundation in 2019 include...
than $27,000 from PACs of pharmaceutical companies, including Astellas, Sunovion, Takeda, Horizon, Eli Lilly, Abbvie, Alexion and Lundbeck ... According...
Schizophrenia with Dr. Stephen M. Stahl, University of Bristol" (PDF). Sunovion Pharmaceuticals Europe Ltd. 2015. "Honorary Doctorate Title presented to...
but was marketed only under the first name. In the US it is marketed by Sunovion (formerly Sepracor) and was approved in November 2013. Studies for the...
healthcare investigators to collect medical quality data for research. In 2017, Sunovion used Embrace in a phase 4 clinical study of Aptiom, a drug meant to reduce...
distribute it as Zebinix or Exalief in Europe. In America it is marketed by Sunovion under the name Aptiom. Its use in epilepsy treatment in children is under...
National Brain Disorders Prize, University of British Columbia 2020 Sumitomo/Sunovion Brain Health Clinical Research Award, CINP 2020 Colvin Prize in Mood Disorders...
2022 International College of Neuropsychopharmacology (CINP) - Sumimoto/Sunovion Brain Health Basic Research Award 2020 McGill Principal's prize for public...
International College of Neuropsychopharmacology with the CINP Sumitomo/Sunovion Brain Health Clinical Research Award and has been appointed as a member...
Global Information